Dianthus Therapeutics (DNTH) Amortization of Deferred Charges (2022 - 2025)
Dianthus Therapeutics (DNTH) posted quarterly Amortization of Deferred Charges of $72000.0 for Q3 2025, down 20.88% year-over-year from $91000.0 in Q3 2024, and up 4.35% quarter-over-quarter from $69000.0 in Q2 2025.
Dianthus Therapeutics (DNTH) Amortization of Deferred Charges (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $72000.0 for Q3 2025.
- In Q3 2025, Amortization of Deferred Charges fell 20.88% year-over-year to $72000.0; the TTM figure through Sep 2025 stood at $299000.0 (down 13.83% YoY), while the FY2024 annual figure was $316000.0, up 9.72% from the prior year.
- Amortization of Deferred Charges for Q3 2025 stood at $72000.0, up from $69000.0 in the prior quarter.
- The five-year high for Amortization of Deferred Charges was $699000.0 in Q1 2022, with the low at $38000.0 in Q4 2022.
- The 4-year median for Amortization of Deferred Charges is $72000.0 (2025), against an average of $122153.8.
- Peak annual rise in Amortization of Deferred Charges reached 118.42% in 2023, while the deepest fall reached 90.41% in 2023.
- Dianthus Therapeutics' Amortization of Deferred Charges stood at $38000.0 in 2022, then soared by 118.42% to $83000.0 in 2023, then plunged by 37.35% to $52000.0 in 2024, then surged by 38.46% to $72000.0 in 2025.
- Business Quant data shows DNTH's Amortization of Deferred Charges at $72000.0 in Q3 2025, $69000.0 in Q2 2025, and $106000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dianthus Therapeutics | 4.97 Bn | 4.57 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 72,000.00 |
| Sep 30, 2025 | 72,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Mar 31, 2025 | 106,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Dec 31, 2024 | 52,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Sep 30, 2024 | 91,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 88,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Mar 31, 2024 | 85,000.00 |
| Dec 31, 2023 | 83,000.00 |
| Dec 31, 2023 | 83,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Sep 30, 2023 | 68,000.00 |
| Jun 30, 2023 | 70,000.00 |
| Jun 30, 2023 | 70,000.00 |